Q32 Bio Inc.

QTTB Healthcare Biotechnology

Q32 Bio Inc.’s revenue for fiscal 2025 (year ended December 2025) was $53.7 million.

EPS
+43.6%
Free cash flow
+71.1%
Total debt
−35.6%

Quarter to June 2026, against a year earlier

9.25 0.40 +4.52%
Market cap
$263.5M
P/E
3.1×
Fwd P/E
−6.2×
Dividend yield
—
F-score
n/a
Altman Z
−0.78
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
4.57 4.85 5.36 20.30
Net Debt/EBITDA
5.08 4.99 5.60 11.68
Debt/Equity
(0.61) 0.23 0.18 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.35) 0.07 (0.45) (0.15)
Book value per Share
(1.51) 3.42 3.29 5.21
Free Cash Flow
(4.23) 0.82 (6.34) (3.07)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates · fundamentals updated 26 Oct 2026